Forrest A - Search Results

1

Use of adaptive control with feedback to individualize suramin dosing.

Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A. Scher HI, et al. Among authors: forrest a. Cancer Res. 1992 Jan 1;52(1):64-70. Cancer Res. 1992. PMID: 1727387

2

A limited sampling strategy for cyclophosphamide pharmacokinetics.

Egorin MJ, Forrest A, Belani CP, Ratain MJ, Abrams JS, Van Echo DA. Egorin MJ, et al. Among authors: forrest a. Cancer Res. 1989 Jun 1;49(11):3129-33. Cancer Res. 1989. PMID: 2720671

3

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

Conley BA, Forrest A, Egorin MJ, Zuhowski EG, Sinibaldi V, Van Echo DA. Conley BA, et al. Among authors: forrest a. Cancer Res. 1989 Jun 15;49(12):3436-40. Cancer Res. 1989. PMID: 2720696

4

Approaches to optimal dosing of hexamethylene bisacetamide.

Conley BA, Egorin MJ, Sinibaldi V, Sewack G, Kloc C, Roberts L, Zuhowski EG, Forrest A, Van Echo DA. Conley BA, et al. Among authors: forrest a. Cancer Chemother Pharmacol. 1992;31(1):37-45. doi: 10.1007/BF00695992. Cancer Chemother Pharmacol. 1992. PMID: 1333894

5

Use of plasma cytotoxic activity to model cytotoxic pharmacodynamics of anticancer drugs.

de Valeriola DL, Ross DD, Forrest A, Cuddy DP, Egorin MJ. de Valeriola DL, et al. Among authors: forrest a. Cancer Chemother Pharmacol. 1991;29(2):133-40. doi: 10.1007/BF00687323. Cancer Chemother Pharmacol. 1991. PMID: 1760856

6

Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.

Egorin MJ, Conley BA, Forrest A, Zuhowski EG, Sinibaldi V, Van Echo DA. Egorin MJ, et al. Among authors: forrest a. Cancer Res. 1987 Nov 15;47(22):6104-10. Cancer Res. 1987. PMID: 2959359

7

Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.

Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J. Egorin MJ, et al. Among authors: forrest a. Cancer Res. 1987 Jan 15;47(2):617-23. Cancer Res. 1987. PMID: 3791246

8

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum.

Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Egorin MJ, et al. Among authors: forrest a. Cancer Res. 1985 Dec;45(12 Pt 1):6502-6. Cancer Res. 1985. PMID: 3904984

9

Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.

Egorin MJ, Van Echo DA, Whitacre MY, Forrest A, Sigman LM, Engisch KL, Aisner J. Egorin MJ, et al. Among authors: forrest a. Cancer Res. 1986 Mar;46(3):1513-20. Cancer Res. 1986. PMID: 2935249

10

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.

Trump DL, Egorin MJ, Forrest A, Willson JK, Remick S, Tutsch KD. Trump DL, et al. Among authors: forrest a. J Clin Oncol. 1991 Nov;9(11):2027-35. doi: 10.1200/JCO.1991.9.11.2027. J Clin Oncol. 1991. PMID: 1941062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,082 results

Search Page

Filters